Indication
Fallopian Tube Carcinoma
21 clinical trials
29 products
9 drugs
Clinical trial
A Phase I Open-Label, Dose-escalation Trial of Tumor Necrosis Factor Alpha and Interleukin-2 Coding Oncolytic Adenovirus (TILT-123) in Combination With Pembrolizumab in Patients With Platinum Resistant or Refractory Ovarian CancerStatus: Recruiting, Estimated PCD: 2024-06-01
Product
TILT-123Product
pembrolizumabClinical trial
A Multi-center, Open-label, Phase I/Ib Study to Assess the Safety, Pharmacokinetics and Anti-tumor Activity of RP12146, a Poly (ADP-ribose) Polymerase (PARP) Inhibitor, in Patients With Locally Advanced or Metastatic Solid TumorsStatus: Completed, Estimated PCD: 2024-04-25
Product
RP12146Clinical trial
Phase I/Ib Study Evaluating Safety and Efficacy of PRGN-3005 UltraCAR-T® (Autologous CAR T Cells) in Advanced Stage Platinum Resistant Ovarian Cancer PatientsStatus: Recruiting, Estimated PCD: 2024-12-15
Product
PRGN-3005Clinical trial
Phase Ib Clinical Investigation of Intraperitoneal Ipilimumab and Nivolumab in Patients With Peritoneal Carcinomatosis Due to Gynecologic CancersStatus: Active (not recruiting), Estimated PCD: 2025-04-30
Drug
T-VECClinical trial
A Phase I, Open Label Study Evaluating the Safety and Efficacy of Adoptive Transfer of Autologous NY-ESO-1 CD8-TCR Engineered T Cells and NY-ESO-1 CD4-TCR Engineered Hematopoietic Stem Cells (HSC) After a Myeloablative Conditioning Regimen, With Administration of IL-2 in Patients With Recurrent or Treatment Refractory Ovarian, Fallopian Tube or Primary Peritoneal CancerStatus: Active (not recruiting), Estimated PCD: 2021-01-30
Product
AldesleukinDrug
MelphalanClinical trial
Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or ThoraxStatus: Recruiting, Estimated PCD: 2026-09-01
Drug
AtezolizumabProduct
CabozantinibDrug
AbraxaneClinical trial
A Randomized Phase II Trial Comparing the Combination of PI3K Inhibitor Copanlisib (BAY 80-6946) and PARP Inhibitor Olaparib (AZD2281) to Standard Chemotherapy in Patients With Recurrent Platinum Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Progressed Through Prior PARP Inhibitor TherapyStatus: Withdrawn, Estimated PCD: 2023-03-17
Product
CopanlisibClinical trial
A Phase 1 Study of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial CancersStatus: Recruiting, Estimated PCD: 2026-06-01
Product
CobimetinibProduct
PelcitoclaxProduct
OlaparibProduct
PaclitaxelProduct
TopotecanClinical trial
A Pilot Study of Wee1 Inhibition Induction Prior to Tumor Reductive Surgery in Ovarian CancerStatus: Active (not recruiting), Estimated PCD: 2026-12-31
Drug
AdavosertibClinical trial
Randomized Phase II Trial of Durvalumab (MEDI4736) and Tremelimumab Administered in Combination Versus Sequentially in Recurrent Platinum-Resistant Epithelial Ovarian CancerStatus: Recruiting, Estimated PCD: 2024-12-15
Product
DurvalumabProduct
TremelimumabClinical trial
Phase 1 Dose Escalation and Expansion Cohort of Carboplatin and Gemcitabine With or Without M6620 (VX-970) in First or Second Recurrence Platinum-Sensitive Epithelial Ovarian, Peritoneal, and Fallopian Tube CancerStatus: Active (not recruiting), Estimated PCD: 2024-11-30
Product
BerzosertibProduct
CarboplatinProduct
GemcitabineClinical trial
A Phase II Randomized Trial of Olaparib Versus Olaparib Plus Tremelimumab in Platinum-Sensitive Recurrent Ovarian CancerStatus: Active (not recruiting), Estimated PCD: 2021-07-31
Product
IpilimumabClinical trial
A Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination With Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women With Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior BevacizumabStatus: Active (not recruiting), Estimated PCD: 2023-01-26
Product
CediranibDrug
AN0025Clinical trial
Randomized Phase I/II Study of AVB-S6-500 in Combination With Durvalumab (MEDI4736) in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian CancerStatus: Active (not recruiting), Estimated PCD: 2025-02-28
Product
BatiraxceptDrug
TiragolumabClinical trial
A Pilot Study of the Safety and Immunogenicity of Folate Receptor Alpha Peptide-Loaded Dendritic Cell Vaccination in Patients With Advanced Stage Epithelial Ovarian CancerStatus: Active (not recruiting), Estimated PCD: 2021-07-27
Clinical trial
Phase 1 Trial of Gemcitabine Combined With the Elimusertib (BAY 1895344) ATR Inhibitor With Expansion Cohorts in Advanced Pancreatic and Ovarian CancerStatus: Active (not recruiting), Estimated PCD: 2024-07-01
Product
ElimusertibDrug
GemcitabineClinical trial
A Randomized Phase 1/2 Trial Evaluating the Addition of Tolinapant to Weekly Paclitaxel With or Without Bevacizumab in Patients With Recurrent Epithelial Ovarian CancerStatus: Not yet recruiting, Estimated PCD: 2028-02-09
Product
TolinapantClinical trial
Phase IB Trial of Niraparib and TSR-042 in Patients With BRCA-Mutated Breast, Pancreas or Ovary CancerStatus: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
Phase II Study of ONC201 Plus Weekly Paclitaxel in Patients With Platinum-Resistant Refractory or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerStatus: Recruiting, Estimated PCD: 2025-05-28
Product
Akt/ERK Inhibitor ONC201Clinical trial
An Early Phase I Study of the Pharmacodynamics of WEE1 Inhibitor, ZN-c3, in Metastatic Solid TumorsStatus: Withdrawn, Estimated PCD: 2024-09-30
Product
Wee1 Inhibitor ZN-c3Clinical trial
Phase 1 Clinical Trial Using Autologous, MUC1-Activated T Cells Expanded From Peripheral Blood in Patients With Relapsed and Resistant Ovarian CancerStatus: Not yet recruiting, Estimated PCD: 2028-09-01
Product
BendamustineDrug
cyclophosphamide